SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$253M
Q1 2024
Positions
72
Filings on Record
25
2019–present window
Filed
May 15, 2024
original filing

Summary

Altium Capital Management LLC reported $253M in U.S.-listed holdings across 72 positions for Q1 2024.

Its largest position, VERA, represents 12.1% of the portfolio.

Compared with Q4 2023, the fund opened 29 new positions and exited 23.

Portfolio Metrics

Turnover
+20.0%
vs prior filed quarter
Top-10 Concentration
+46.9%
share of reported value
Largest Position
+12.1%
Vera Therapeutics
New / Exited
29 / 23
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $268MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 77.7%Other: 21.7%Equity WRT: 0.6%
  • Common Stock · 77.7% · $196M
  • Other · 21.7% · $55M
  • Equity WRT · 0.6% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VIKING THERAPEUTICS INCNEW+175.3K175.3K+$14M$14M
ADVISORSHARES TRNEW+1.13M1.13M+$11M$11M
AVADEL PHARMACEUTICALS PLCNEW+553.1K553.1K+$9M$9M
BHVNBIOHAVEN LTDNEW+140.0K140.0K+$8M$8M
VKTXVIKING THERAPEUTICS INCNEW+85.0K85.0K+$7M$7M
CYBIN INCNEW+13.95M13.95M+$6M$6M
LRMRLARIMAR THERAPEUTICS INCNEW+695.0K695.0K+$5M$5M
MIRMMIRUM PHARMACEUTICALS INCNEW+208.0K208.0K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

68 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1VERAVERA THERAPEUTICS INChistory →CL A12.12%$31M710.0K
2XENEXENON PHARMACEUTICALS INChistory →COM5.93%$15M348.0K
3AXSMAXSOME THERAPEUTICS INChistory →COM4.36%$11M138.0K
4ADMAADMA BIOLOGICS INChistory →COM4.02%$10M1.54M
5ALIMERA SCIENCES INCCOM NEW3.94%$10M2.55M
6AVADEL PHARMACEUTICALS PLCSPONSORED ADR3.70%$9M553.1K
7XTNTXTANT MED HLDGS INChistory →COM NEW3.54%$9M7.65M
8CN2CATALYST PHARMACEUTICALS INChistory →COM3.15%$8M500.0K
9INTRA-CELLULAR THERAPIES INCCOM3.09%$8M113.0K
10BHVNBIOHAVEN LTDhistory →COM3.03%$8M140.0K
11VKTXVIKING THERAPEUTICS INChistory →COM2.76%$7M85.0K
12OLMAOLEMA PHARMACEUTICALS INChistory →COM2.71%$7M605.0K
13SVRASAVARA INChistory →COM2.63%$7M1.33M
14SOLENO THERAPEUTICS INCCOM2.59%$7M152.9K
15CYBIN INCCOM2.28%$6M13.95M
16ORICORIC PHARMACEUTICALS INChistory →COM2.20%$6M405.0K
17LRMRLARIMAR THERAPEUTICS INChistory →COM2.09%$5M695.0K
18MIRMMIRUM PHARMACEUTICALS INChistory →COM2.07%$5M208.0K
19NGNENEUROGENE INChistory →COM2.01%$5M100.0K
20PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW1.89%$5M78.1K
21ACHVACHIEVE LIFE SCIENCES INChistory →COM1.50%$4M835.5K
22ASNDASCENDIS PHARMA A/Shistory →SPONSORED ADR1.50%$4M25.0K
23LONGBOARD PHARMACEUTICALS INCOM1.45%$4M170.0K
24INSMINSMED INChistory →COM PAR $.011.29%$3M120.0K
25REALTHE REALREAL INChistory →COM1.24%$3M800.0K
26ALPINE IMMUNE SCIENCES INCCOM1.22%$3M77.8K
27BOLDBOUNDLESS BIO INChistory →COM1.13%$3M200.0K
28AQSTAQUESTIVE THERAPEUTICS INChistory →COM1.12%$3M665.0K
29RYTMRHYTHM PHARMACEUTICALS INCCOM0.98%$2M57.3K
30MISTMILESTONE PHARMACEUTICALS INCOM0.86%$2M1.21M
31ASTRIA THERAPEUTICS INCCOM0.79%$2M142.5K
32ZVRAZEVRA THERAPEUTICS INCCOM NEW0.78%$2M341.5K
33MARINUS PHARMACEUTICALS INCCOM NEW0.63%$2M176.8K
34BIOVIE INCCL A NEW0.63%$2M3.01M
35TRMLTOURMALINE BIO INCCOM0.59%$1M65.4K
36VERU INCCOM0.59%$1M2.11M
37KARYOPHARM THERAPEUTICS INCCOM0.44%$1M740.0K
38FAT BRANDS INC*W EXP 07/16/2020.39%$974,000200.0K
39SPRUCE BIOSCIENCES INCCOM0.36%$903,7851.15M
40PERSPECTIVE THERAPEUTICS INCCOM0.25%$637,432535.7K
41EVOKE PHARMA INCCOM NEW0.18%$442,215724.9K
42PMNTPERFECT MOMENT LTDCOM SHS0.13%$330,10592.2K
43RCKTWROCKET PHARMACEUTICALS INC*W EXP 09/02/2020.09%$218,883731.6K
44NXGLWNEXGEL INC*W EXP 12/01/2020.06%$162,000225.0K
45MOBILICOM LTDSPON ADS0.06%$160,997135.3K
46GRI BIO INCCOM NEW0.06%$142,866188.0K
47WEARABLE DEVICES LTD*W EXP 09/14/2020.04%$109,4701.41M
48AZITRA INCCOM0.04%$101,343493.2K
49NOCTURNE ACQUISITION CORPRIGHT 12/26/20250.03%$82,000500.0K
50QUOIN PHARMACEUTICALS LTDSPONSORED ADS0.02%$62,92866.2K
51MOBIX LABS INC*W EXP 99/99/9990.01%$31,500150.0K
52DIGITAL HEALTH ACQUISITION C*W EXP 99/99/9990.01%$19,245150.0K
53ONFOWONFOLIO HOLDINGS INC*W EXP 01/02/2020.00%$8,120200.0K
54NLS PHARMACEUTICS LTD*W EXP 02/02/2020.00%$6,880200.0K
55CONDUIT PHARMACEUTICALS INC*W EXP 09/22/2020.00%$6,000100.0K
56CINGWCINGULATE INC*W EXP 12/10/2020.00%$5,697270.0K
57BTMWQBITCOIN DEPOT INC*W EXP 06/30/2020.00%$4,74550.0K
58NEXALIN TECHNOLOGY INC*W EXP 99/99/9990.00%$4,389105.0K
59CYCUWWESTERN ACQSTN VENTURES CORP*W EXP 99/99/9990.00%$4,275100.0K
60JEFFS BRANDS LTD*W EXP 99/99/9990.00%$4,01168.7K
61SRZNWSURROZEN INC*W EXP 08/01/2030.00%$3,40482.2K
62BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.00%$3,250250.0K
63PROSOMNUS INC*W EXP 04/20/2020.00%$3,000150.0K
64COLISEUM ACQUISITION CORP*W EXP 08/22/2020.00%$1,87028.3K
65SELINA HOSPITALITY PLC*W EXP 10/27/2020.00%$710101.4K
66TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/10/2020.00%$37618.8K
67BRSWFBRUUSH ORAL CARE INC*W EXP 08/03/2020.00%$11014.4K
68RELATIVITY ACQUISITION CORP*W EXP 12/15/2020.00%$0100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$268M95May 5, 2021RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.